A comprehensive review of how researchers are modifying the human antimicrobial peptide LL-37 to overcome its limitations and develop it into a viable treatment for drug-resistant infections.
Only human cathelicidinLL-37 is the only cathelicidin antimicrobial peptide produced by the human body, making it a natural starting point for developing new anti-infective therapies
What the researchers found
This comprehensive review examines how scientists have modified LL-37 — the only human cathelicidin antimicrobial peptide — to overcome its key limitations: high production costs, reduced effectiveness under real physiological conditions, vulnerability to enzymatic breakdown, and toxicity to human cells.
Multiple modification strategies have improved LL-37's clinical potential, including truncation (shortening the peptide while keeping its active region), amino acid substitutions, cyclization, and conjugation with nanocarrier delivery systems. Modified LL-37 derivatives show enhanced activity against bacterial biofilms and cell membranes, and some demonstrate synergy with traditional antibiotics.
Why it matters
Antibiotic resistance is one of the biggest threats to modern medicine, and antimicrobial peptides like LL-37 represent a fundamentally different approach to fighting infections. Unlike conventional antibiotics that target specific bacterial processes, LL-37 physically disrupts bacterial membranes — making it harder for bacteria to develop resistance. This review maps the path from a promising natural peptide to potentially viable clinical treatments.
How the study worked
Narrative review of the scientific literature on LL-37 modification techniques, structure-activity relationships, mechanisms of action, nanocarrier delivery systems, and clinical application status.
Who was studied
Review of published research — no direct study population
What this study cannot tell us
As a review article, this synthesizes existing research rather than generating new data. The clinical translation of most LL-37 derivatives is still in early stages, and many findings come from in vitro or animal studies.
How to read the evidence
This is a review article that synthesizes findings from many individual studies. It provides a comprehensive overview of the field but does not generate new experimental data. The evidence quality of the underlying studies varies from in vitro to early clinical work.
When this study was published
Published in 2025, this review captures the latest developments in LL-37 derivative research including recent nanocarrier delivery advances and clinical translation efforts.
The bigger picture
With antibiotic-resistant superbugs becoming a growing global health crisis, antimicrobial peptides are attracting intense research interest as a new class of anti-infective drugs. LL-37 is especially promising because it's a natural part of human immunity, but turning it into an actual medication requires solving real engineering challenges. This review shows how close — and how far — we are from LL-37-based drugs.
Questions still open
- Which LL-37 modification strategy offers the best balance of antimicrobial potency, safety, and manufacturing cost?
- Can LL-37 derivatives combined with traditional antibiotics help rescue drugs that bacteria have already become resistant to?
- How will nanocarrier delivery systems affect the pharmacokinetics and tissue targeting of LL-37 derivatives in humans?
Common questions
What is LL-37 and why is it important?
Why can't LL-37 be used as a drug in its natural form?
Read the original research
Exploring the Antimicrobial Potential of LL-37 Derivatives: Recent Developments and Challenges.
ACS biomaterials science & engineering, 11(6), 3145-3164
Citation
Yuan, Yihao; Li, Jiapeng; Wei, Guotao; Shen, Ziyi; Li, Bo; Wu, Jiawei; Liu, Jing. (2025). Exploring the Antimicrobial Potential of LL-37 Derivatives: Recent Developments and Challenges.. ACS biomaterials science & engineering, 11(6), 3145-3164. https://doi.org/10.1021/acsbiomaterials.4c02029